U.S. Food and Drug Administration • Center for Drug Evaluation and ResearchSkip navigation
CDER - Center for Drug Evaluation and Research Logo

Drug Information

CDER Home Site Information Comments and Feedback What's New CDER Navigation Bar

CDER ArchivesSpecific AudiencesCDER CalendarRegulatory InformationDrug InformationAbout CDERSide Navigational Buttons

Iressa (gefitinib)

The Food and Drug Administration today announced the approval of Iressa (gefitinib).  Iressa is a new anticancer drug that inhibits an enzyme (tyrosine kinase) present in lung cancer cells, as well as other cancers and normal tissues, that appears to be important to the growth of cancer cells. Iressa is used as a single agent for the treatment of non-small cell lung cancer (NSCLC) that has progressed after, or failed to respond to two other types of chemotherapy (drugs used to kill cancer cells).

totop.gif (1525 bytes) Back to Top   Back Back to Drug Information

FDA/Center for Drug Evaluation and Research
Created: May 5, 2003; Last Updated: May 13, 2003
Originator: OTCOM/DLIS
HTML by SJW